• Craig H Fletcher, Melkon G DomBourian, and Peter A Millward.
• Beaumont Health, Royal Oak, MI 48073, USA. Craig.Fletcher@Beaumont.edu.
• Cancer Control. 2015 Jan 1;22(1):47-51.

BackgroundPlatelet transfusion is a critical and often necessary aspect of managing cancer. Low platelet counts frequently lead to bleeding complications; however, the drugs used to combat malignancy commonly lead to decreased production and destruction of the very cell whose function is essential to stop bleeding. The transfusion of allogeneic platelet products helps to promote hemostasis, but alloimmunization may make it difficult to manage other complications associated with cancer.MethodsThe literature relating to platelet transfusion in patients with cancer was reviewed.ResultsPlatelet storage, dosing, transfusion indications, and transfusion response are essential topics for health care professionals to understand because many patients with cancer will require platelet transfusions during the course of treatment. The workup and differentiation of non-immune-mediated compared with immune-mediated platelet refractoriness are vital because platelet management is different between types of refractoriness.ConclusionsA combination of appropriate utilization of platelet inventory and laboratory testing coupled with communication between those caring for patients with cancer and those providing blood products is essential for effective patient care.

13 keywords...

hide…